Literature DB >> 23905004

Determining benchmarks in hearing preservation surgery for vestibular schwannoma.

Michael B Gluth1, John D Day, John L Dornhoffer.   

Abstract

Objectives The objectives of this study were to determine minimal benchmarks of success in vestibular schwannoma hearing preservation surgery, wherein the likelihood of having preserved hearing in a single patient is at least as likely as having created a poor facial nerve outcome for a single patient. Design This is a statistical analysis of published literature. Setting Academic Tertiary Medical Center. Main Outcome Measures Based on published natural history data, the number needed to treat (NNT) equation was used to calculate the minimally acceptable hearing preservation rates within various hearing classification schemes. Results Given good facial nerve outcome rates of 85, 90, and 95%, the corresponding hearing preservation rates at 4.7 years that are likely to preserve classes A and B hearing (American Academy of Otolaryngology-Head and Neck Surgery classification) in a single patient as to cause a poor facial nerve outcome are 70, 65, and 60%, respectively. If surgery is limited exclusively to intracanalicular tumors, these rates drop to 62, 57, and 52%, respectively. If the word recognition scoring classification is used, required hearing preservation rates are higher. Conclusion It is possible to use the NNT equation alongside projected facial nerve outcomes to estimate benchmarks of minimally acceptable hearing preservation rates.

Entities:  

Keywords:  acoustic neuroma; hearing preservation; number needed to treat; vestibular schwannoma

Year:  2012        PMID: 23905004      PMCID: PMC3424036          DOI: 10.1055/s-0032-1312710

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  32 in total

1.  Small acoustic neuromas: surgical outcomes versus observation or radiation.

Authors:  Ted A Meyer; Paul A Canty; Eric P Wilkinson; Marlan R Hansen; Jay T Rubinstein; Bruce J Gantz
Journal:  Otol Neurotol       Date:  2006-04       Impact factor: 2.311

2.  Hearing preservation in acoustic neuroma surgery: middle fossa versus retrosigmoid approach.

Authors:  H Staecker; J B Nadol; R Ojeman; S Ronner; M J McKenna
Journal:  Am J Otol       Date:  2000-05

3.  Conservative management of unilateral acoustic neuromas.

Authors:  D C Tschudi; T E Linder; U Fisch
Journal:  Am J Otol       Date:  2000-09

4.  The number needed to treat: a clinically useful measure of treatment effect.

Authors:  R J Cook; D L Sackett
Journal:  BMJ       Date:  1995-02-18

5.  Selection of surgical approaches for small acoustic neurinomas.

Authors:  Y Kumon; S Sakaki; K Kohno; S Ohta; K Nakagawa; S Ohue; S Murakami; N Yanagihara
Journal:  Surg Neurol       Date:  2000-01

6.  Risk-benefit analysis of using the middle fossa approach for acoustic neuromas with >10 mm cerebellopontine angle component.

Authors:  Bulent Satar; Robert K Jackler; John Oghalai; Lawrence H Pitts; Philip D Yates
Journal:  Laryngoscope       Date:  2002-08       Impact factor: 3.325

7.  Hearing preservation after intracanalicular vestibular schwannoma radiosurgery.

Authors:  Ajay Niranjan; David Mathieu; John C Flickinger; Douglas Kondziolka; L Dade Lunsford
Journal:  Neurosurgery       Date:  2008-12       Impact factor: 4.654

8.  Conservative management of vestibular schwannomas - second review of a prospective longitudinal study.

Authors:  V V Raut; R M Walsh; A P Bath; M L Bance; A Guha; C H Tator; J A Rutka
Journal:  Clin Otolaryngol Allied Sci       Date:  2004-10

9.  Middle fossa versus retrosigmoid-transmeatal approach in vestibular schwannoma surgery: a prospective study.

Authors:  Vittorio Colletti; Francesco Fiorino
Journal:  Otol Neurotol       Date:  2003-11       Impact factor: 2.311

10.  Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology-Head and Neck Surgery Foundation, INC.

Authors: 
Journal:  Otolaryngol Head Neck Surg       Date:  1995-09       Impact factor: 3.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.